Clinical characteristics and efficacy of CP/CPPS IIIa treatment in patients with abdominal obesity

Background: obesity is defined as excessive accumulation of adipose tissue in the body, adversely affecting health. Given the established pathogenic correlations between abdominal obesity (AO) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), investigation of the AO impact on the CP/CPPS manifestations represents a relevant focus in contemporary uroandrology Aim: to identify the clinical patterns, laboratory and instrumental findings, and to evaluate the efficacy of therapeutic approaches in young patients with CP/CPPS IIIa and concomitant AO Materials and Methods: between 2018 and 2022, a comprehensive urological examination was performed on 150 young men (aged 18–44 years) diagnosed with CP/CPPS IIIa. The assessment included validated questionnaires (NIH-CPSI, SFM) Treatment efficacy was analyzed in patient groups stratified by the presence of AO (waist circumference ≥94 cm). Results: in patients with AO, the clinical profile of CP/CPPS IIIa, as determined by the NIH-CPSI, was characterized by more pronounced pain and voiding symptoms, as well as lower disease-specific quality of life scores. SFM domains evaluating libido, erectile function, ejaculation, sexual satisfaction, and overall psychological assessment of sexual activity were significantly lower in the AO group. Hormonal imbalance, mainly due to elevated estriol levels, was observed in patients with AO. Considering the greater severity of symptoms in the AO group, a prostate extract preparation was added to the standard therapeutic regimen. By week 4, a significant reduction in CP/CPPS symptoms was noted in both groups Conclusion: the most severe clinical manifestations of CP/CPPS were found in men with AO Active identification and timely management of AO by interdisciplinary specialists are necessary for the prevention of male reproductive system disorders The use of a prostate extract preparation as part of combination therapy for CP/CPPS in men with AO has shown effectiveness KEYWORDS: chronic prostatitis, pelvic pain, abdominal obesity, somatometry. FOR CITATION: Vinnik Yu.Yu., Amelchenko A.A. Clinical characteristics and efficacy of CP/CPPS IIIa treatment in patients with abdominal obesity. Russian Medical Inquiry. 2025;9(4):223–228 (in Russ.). DOI: 10.32364/2587-6821-2025-9-4-6

Authors

Publication Details

Journal
Russian Medical Inquiry
Published
2025-01-01
DOI
https://doi.org/10.32364/2587-6821-2025-9-4-6
Primary Topic
Cardiovascular Function and Risk Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical characteristics and efficacy of CP/CPPS IIIa treatment in patients with abdominal obesity

Andrei A. Amelchenko, Yu. S. Vinnik
Russian Medical Inquiry
Cardiovascular Function and Risk Factors
article

Clinical characteristics and efficacy of CP/CPPS IIIa treatment in patients with abdominal obesity

Andrei A. Amelchenko, Yu. S. Vinnik
article en

Abstract

Background: obesity is defined as excessive accumulation of adipose tissue in the body, adversely affecting health. Given the established pathogenic correlations between abdominal obesity (AO) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), investigation of the AO impact on the CP/CPPS manifestations represents a relevant focus in contemporary uroandrology Aim: to identify the clinical patterns, laboratory and instrumental findings, and to evaluate the efficacy of therapeutic approaches in young patients with CP/CPPS IIIa and concomitant AO Materials and Methods: between 2018 and 2022, a comprehensive urological examination was performed on 150 young men (aged 18–44 years) diagnosed with CP/CPPS IIIa. The assessment included validated questionnaires (NIH-CPSI, SFM) Treatment efficacy was analyzed in patient groups stratified by the presence of AO (waist circumference ≥94 cm). Results: in patients with AO, the clinical profile of CP/CPPS IIIa, as determined by the NIH-CPSI, was characterized by more pronounced pain and voiding symptoms, as well as lower disease-specific quality of life scores. SFM domains evaluating libido, erectile function, ejaculation, sexual satisfaction, and overall psychological assessment of sexual activity were significantly lower in the AO group. Hormonal imbalance, mainly due to elevated estriol levels, was observed in patients with AO. Considering the greater severity of symptoms in the AO group, a prostate extract preparation was added to the standard therapeutic regimen. By week 4, a significant reduction in CP/CPPS symptoms was noted in both groups Conclusion: the most severe clinical manifestations of CP/CPPS were found in men with AO Active identification and timely management of AO by interdisciplinary specialists are necessary for the prevention of male reproductive system disorders The use of a prostate extract preparation as part of combination therapy for CP/CPPS in men with AO has shown effectiveness KEYWORDS: chronic prostatitis, pelvic pain, abdominal obesity, somatometry. FOR CITATION: Vinnik Yu.Yu., Amelchenko A.A. Clinical characteristics and efficacy of CP/CPPS IIIa treatment in patients with abdominal obesity. Russian Medical Inquiry. 2025;9(4):223–228 (in Russ.). DOI: 10.32364/2587-6821-2025-9-4-6

Russian Medical InquiryVol. 9(4)
Openalex Percentile: Top 73%
Cardiovascular Function and Risk Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Clinical characteristics and efficacy of CP/CPPS IIIa treatment in patients with abdominal obesity — Andrei A. Amelchenko, Yu. S. Vinnik · Russian Medical Inquiry (2025) | TGRS Research Map | TGRS